Kiniksa Pharmaceuticals Ltd (KNSA)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $7.57B
Last updated: Nov 17, 2026 at 11:06 AM ET
Kiniksa Pharmaceuticals Ltd (KNSA) Stock Forecast
Analysts expect Kiniksa Pharmaceuticals (KNSA) to earn $1.50 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.05B. Of 8 analysts, 8 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 1.88, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 12.5% |
| Buy | 7 | 87.5% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 8
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 45.3% and revenue estimates rise 25.7%.
- Fiscal year ending Dec 31, 2026
- $1.50
- EPS consensus, revenue $1.05B
- Fiscal year ending Dec 31, 2027
- $2.18
- EPS consensus, revenue $1.32B
- Next report
- Feb 22, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.50 | $1.22 to $1.91 | 4 | $1.05B | $1.05B to $1.05B | 7 |
| Dec 31, 2027 | $2.18 | $1.59 to $2.80 | 4 | $1.32B | $1.24B to $1.38B | 7 |
Quarterly Estimates
The EPS consensus rises from $0.29 for the quarter ending Dec 31, 2026 to $0.44 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.29 | $0.16 to $0.43 | 9 | $312.68M | $296.84M to $330.33M | 9 |
| Mar 31, 2027 | $0.44 | $0.29 to $0.55 | 4 | $313.78M | $310.00M to $320.90M | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 4 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 2 | 0 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 29.3% from $1.16.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $1.50 | $1.16 | $1.16 | $1.16 | $1.16 | +29.2% |
| Fiscal year ending Dec 31, 2027 | $2.18 | $1.62 | $1.62 | $1.62 | $1.62 | +34.9% |
| Quarter ending Mar 31, 2027 | $0.44 | $0.36 | $0.36 | $0.36 | $0.36 | +22.2% |
Frequently Asked Questions About KNSA
What is the KNSA stock forecast?
Consensus analyst estimates put Kiniksa Pharmaceuticals's EPS at $1.50 for the fiscal year ending Dec 31, 2026, on revenue of $1.05B. The consensus rating from 8 analysts is Buy.
How do analysts rate KNSA stock?
Of 8 analysts covering Kiniksa Pharmaceuticals, 1 rates it Strong Buy, 7 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from KNSA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $1.50, with estimates from $1.22 to $1.91 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $2.18, with estimates from $1.59 to $2.80 from 4 analysts.
What revenue do analysts expect from Kiniksa Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.05B, with estimates from $1.05B to $1.05B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.32B, with estimates from $1.24B to $1.38B.
How many analysts cover KNSA?
8 analysts rate Kiniksa Pharmaceuticals stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
KNSA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts